Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.

NCT Number	NCT07064005
Lead Sponsor	Pravat Mandal Collaborators: Waste Connections Inc
Conditions	Parkinsons Disease (PD)
Enrollment	12 participants
Start Date	2026-03-23
Primary Completion	2027-09 (estimated)
Study Completion	2027-11-27 (estimated)
Updated on ClinicalTrials.gov	2026-05-04